155 related articles for article (PubMed ID: 9815922)
21. BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to alpha-folate receptor-overexpressing tumors.
Gibbs DD; Theti DS; Wood N; Green M; Raynaud F; Valenti M; Forster MD; Mitchell F; Bavetsias V; Henderson E; Jackman AL
Cancer Res; 2005 Dec; 65(24):11721-8. PubMed ID: 16357184
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
[TBL] [Abstract][Full Text] [Related]
23. Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients.
Beale P; Judson I; Hanwell J; Berry C; Aherne W; Hickish T; Martin P; Walker M
Cancer Chemother Pharmacol; 1998; 42(1):71-6. PubMed ID: 9619761
[TBL] [Abstract][Full Text] [Related]
24. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
25. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
Horton TM; Blaney SM; Langevin AM; Kuhn J; Kamen B; Berg SL; Bernstein M; Weitman S
Clin Cancer Res; 2005 Mar; 11(5):1884-9. PubMed ID: 15756014
[TBL] [Abstract][Full Text] [Related]
27. Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.
Walton MI; Gibson W; Aherne GW; Lawrence N; Stephens TC; Smith MN; Jackman AL
J Pharmacol Exp Ther; 1996 May; 277(2):909-16. PubMed ID: 8627573
[TBL] [Abstract][Full Text] [Related]
28. A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.
Calvert AH; Alison DL; Harland SJ; Robinson BA; Jackman AL; Jones TR; Newell DR; Siddik ZH; Wiltshaw E; McElwain TJ
J Clin Oncol; 1986 Aug; 4(8):1245-52. PubMed ID: 3734849
[TBL] [Abstract][Full Text] [Related]
29. A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor.
Plummer R; Rees C; Hughes A; Beale P; Highley M; Trigo J; Gokul S; Judson I; Calvert H; Jackman A; Mitchell F; Smith R; Douglass E
Clin Cancer Res; 2003 Apr; 9(4):1313-22. PubMed ID: 12684399
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of ZD9331, a nonpolyglutamatable thymidylate synthase inhibitor, given as a 5-day continuous infusion to patients with refractory solid malignancies.
Rees C; Beale P; Trigo JM; Mitchell F; Jackman A; Smith R; Douglass E; Judson I
Clin Cancer Res; 2003 Jun; 9(6):2049-55. PubMed ID: 12796367
[TBL] [Abstract][Full Text] [Related]
31. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacokinetics of antitumor antifolates.
Newell DR
Semin Oncol; 1999 Apr; 26(2 Suppl 6):74-81. PubMed ID: 10598559
[TBL] [Abstract][Full Text] [Related]
33. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity.
Synold TW; Newman EM; Carroll M; Muggia FM; Groshen S; Johnson K; Doroshow JH
Clin Cancer Res; 1998 Oct; 4(10):2349-55. PubMed ID: 9796964
[TBL] [Abstract][Full Text] [Related]
34. Antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1: in vitro and in vivo studies with prodrugs of methotrexate and the thymidylate synthase inhibitors GW1031 and GW1843.
Wolfe LA; Mullin RJ; Laethem R; Blumenkopf TA; Cory M; Miller JF; Keith BR; Humphreys J; Smith GK
Bioconjug Chem; 1999; 10(1):38-48. PubMed ID: 9893962
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
36. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous i.v. infusion.
Kitchen BJ; Balis FM; Poplack DG; O'Brien M; Craig CE; Adamson PC
Clin Cancer Res; 1997 May; 3(5):713-7. PubMed ID: 9815740
[TBL] [Abstract][Full Text] [Related]
37. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors.
Beutel G; Glen H; Schöffski P; Chick J; Gill S; Cassidy J; Twelves C
Clin Cancer Res; 2005 Aug; 11(15):5487-95. PubMed ID: 16061865
[TBL] [Abstract][Full Text] [Related]
39. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
[TBL] [Abstract][Full Text] [Related]
40. A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies.
Hidalgo M; Rodriguez G; Kuhn JG; Brown T; Weiss G; MacGovren JP; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Nov; 4(11):2763-70. PubMed ID: 9829740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
